Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

FDA strengthens AI regulation to ensure patient safety and innovation in healthcare

The FDA is adapting regulations to manage AI’s rapid development in healthcare, focusing on patient safety and the life cycle of AI tools. This review emphasizes the need for continuous monitoring to ensure AI performs effectively in clinical settings.

16 Oct 2024

Groundbreaking discovery offers hope for patients suffering from toxic epidermal necrolysis

A global team of researchers at the Max Planck Institute of Biochemistry has made a groundbreaking discovery that saves the lives of patients suffering from toxic epidermal necrolysis.

16 Oct 2024

Nuclera closes $75 million USD financing

Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, today announced it has completed a USD $75 million financing round (circa £57 million).

16 Oct 2024

Sapio Sciences enhances bioanalysis LIMS and ELN with advanced immunogenicity capabilities

Sapio Sciences, the science-aware™ lab informatics platform, today announced the addition of new immunogenicity bioanalysis features to its industry-leading lab informatics platform.

From Sapio Sciences 16 Oct 2024

Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery

Ubiquigent Limited (“Ubiquigent”), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases.

From Ubiquigent Limited 16 Oct 2024

Scripps Research identifies binding site on challenging cancer protein

Hormone-driven cancers, like those of the breast and prostate, often rely on a tricky-to-target protein called Forkhead box protein 1 (FOXA1). FOXA1 mutations can enable these types of cancers to grow and proliferate.

15 Oct 2024

New insights on protein degraders open doors to treatment for 'undruggable' diseases

Researchers at the University of Dundee have revealed in the greatest detail yet the workings of molecules called 'protein degraders' which can be deployed to combat what have previously been regarded as 'undruggable' diseases, including cancers and neurodegenerative diseases.

12 Oct 2024

Breakthrough in mirror molecule synthesis opens doors for drug discovery

A University of Texas at Dallas chemist and his colleagues have developed a new chemical reaction that will allow researchers to synthesize selectively the left-handed or right-handed versions of "mirror molecules" found in nature and assess them for potential use against cancer, infection, depression, inflammation and a host of other conditions.

10 Oct 2024

Skin pigmentation may affect drug efficacy and safety

Skin pigmentation may act as a "sponge" for some medications, potentially influencing the speed with which active drugs reach their intended targets, a pair of scientists report in a perspective article published in the journal Human Genomics.

10 Oct 2024

Novel compounds show promise in fighting COVID-19

New research from The Wistar Institute's Salvino lab - led by professor Joseph Salvino, Ph.D. - has identified a novel series of SARS-CoV-2 Mpro inhibitors that may lead to potential new COVID-19 treatments that, according to preclinical testing, effectively inhibits COVID-19 and synergizes with existing anti-COVID therapies.

8 Oct 2024

Clonal competition assays reveal tumor cell resistance mechanisms

All cells within the same cancer are not the same. They all have genetic errors that turn them into tumor cells, but these errors are not identical.

8 Oct 2024

Replicating Lewy body formation in living neurons to understand Parkinson's disease

Lewy bodies are a hallmark of Parkinson's disease (PD) and other related neurological conditions. Understanding why and how they develop is critical to developing better treatments.

8 Oct 2024

Revolutionizing drug discovery with SmartCADD

Drug discovery is much like working a jigsaw puzzle. The chemical compounds behind drug molecules must be shaped to fit with the proteins in our bodies to produce therapeutic effects.

8 Oct 2024

Mosaic Therapeutics appoints Dr Barry Davies as CSO

Dr. Barry Davies joins Mosaic Therapeutics as CSO, bringing 25 years of drug discovery expertise to advance targeted oncology therapies and precision medicine.

8 Oct 2024

New deep-learning framework identifies non-addictive pain relief options

An estimated one in five Americans live with chronic pain and current treatment options leave much to be desired.

7 Oct 2024

Owkin partners with AstraZeneca to enhance gBRCA testing for breast cancer

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

4 Oct 2024

KiNet web portal enhances study of kinase functions in cellular signaling pathways

Researchers from the Icahn School of Medicine at Mount Sinai have introduced KiNet, an interactive web portal designed to explore kinase-substrate interactions in human cellular systems. These interactions play a vital role in modulating complex signaling pathways that control various cellular processes, such as cell growth, differentiation, and response to environmental stimuli.

4 Oct 2024

Novel semi-synthetic compound shows promise against drug-resistant tuberculosis

A new study published in the American Society for Microbiology journal Microbiology Spectrum demonstrates that a novel semi-synthetic compound can be derived from natural compounds to produce potent activity against Mycobacterium tuberculosis, including multi-drug resistant strains.

3 Oct 2024

Researchers make breakthrough in Alzheimer's disease drug development

An international team of researchers led by Lancaster University have made a promising breakthrough in the development of drugs to treat Alzheimer's Disease.

3 Oct 2024

Study uncovers biological drivers of plasma proteins, offering new insights for disease biomarkers and drug discovery

Researchers mapped the biological influences on 4,775 plasma proteins, revealing the interplay of modifiable and non-modifiable factors, with key implications for disease biomarkers and drug targets.

30 Sep 2024